Recruiting
Phase 1
Phase 2

aPBI

Sponsor:

Dartmouth-Hitchcock Medical Center

Code:

NCT07612254

Conditions

Breast Cancer Recurrent

Eligibility Criteria

Sex: All

Age: 40+

Healthy Volunteers: Not accepted

Interventions

Reirradiation

Study Details

Brief summary:

This study is to determine whether acute treatment-associated adverse events following breast re-irradiation with aPBI are acceptably low and to assess local control following breast re-irradiation with aPBI. An exploratory aim is to assess cosmetic outcomes following breast re-irradiation with aPBI.

Conditions

Breast Cancer Recurrent

Study ID

NCT07612254

Start date

Jun 3, 2026

Status verified date

Nov, 2026

Completion date

Apr, 2033

Anticipated

Primary completion date

Apr 28, 2032

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 40+

Healthy Volunteers: Not accepted

Inclusion Criteria

1. Patients who have histologically-confirmed, second, ipsilateral breast cancer which was diagnosed more than one year after completing breast conserving therapy.
2. Patients must have received prior radiotherapy to the breast
3. Patients must have an intact, involved breast.
4. Patients must meet ASTRO 2023 guidelines for a strong recommendation for partial breast irradiation.

  • Grade 1-2 disease
  • ER-positive histology
  • Tumor size up to 2 cm
  • Patient's age 40 or older
5. Patients who will undergo breast radiation therapy at D-H Lebanon, D-H St. Johnsbury, or Cheshire Medical Center.
6. Patients must have a lumpectomy cavity that can be delineated on CT scan.
7. Patients who are able to provide informed consent.
8. Females of childbearing potential must have a negative urine or serum pregnancy test within 14 days of study entry.
9. Females of childbearing potential must not be pregnant and not lactating and willing to use medically acceptable form of contraception during radiation therapy.

Exclusion Criteria

Patients who meet any of the criteria below may NOT participate in this study:

1. Patients who have not received prior radiotherapy to the ipsilateral breast.
2. Patients who do not meet ASTRO 2023 guidelines for a strong recommendation for partial breast irradiation, including those who meet criteria for conditionally recommended, conditionally not recommended, and not recommended for partial breast irradiation.
3. Patients who are < 40 years of age.
4. Patients with breast implants or other breast reconstruction.
5. Patients who received a prior course of aPBI or breast brachytherapy in the ipsilateral breast.
6. Patients who are actively receiving treatment or within 1 year of treatment from another malignancy, excluding non-melanoma skin cancers.
7. Patients who are pregnant.
8. Patients who are unable to provide informed consent.
9. Patients who decline participation in the study.
10. Patients with active systemic lupus erythematosus, or any history of scleroderma, dermatomyositis with active rash are excluded.

Study Design

Enrollment

30 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: aPBI Re-irradiation

Patients who have histologically-confirmed, second, ipsilateral breast cancer which was diagnosed more than one year after completing breast conserving therapy and have received or are receiving re-irradiation for in-breast recurrence of breast cancer.

Interventions

Reirradiation

aPBI, which is routinely used to treat patients who have previously not been irradiated, with a dose of 30 Gy in 5 fractions using a VMAT technique.

Primary outcome measure

  • Treatment-associated toxicity [ Time Frame: Within 1 year ]

Central Contacts and Locations

Locations

Dartmouth-Hitchcock Medical Center

Recruiting

Lebanon, New Hampshire, United States, 03756

Contacts

Principal Investigator:

Lesley A Jarvis

More Information

Sponsor

Dartmouth-Hitchcock Medical Center

Last update posted

Nov 16, 2026

Last verified

Nov, 2026

Keywords

  • Ipsilateral

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-17. This information was provided to ClinicalTrials.gov by Dartmouth-Hitchcock Medical Center on 2026-11-16. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.